

Financial news for HSGX dated on 2019-09-30: 52 Biggest Movers From Friday

Financial news for HSGX dated on 2019-09-27: 21 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for HSGX dated on 2019-09-27: Histogenics shares are trading lower after the company announced its proposed merger with Ocugen was approved by Histogenics' stockholders at a special meeting. NOTE: The stockholders of Ocugen will become majority holders of the combined company.

Financial news for HSGX dated on 2019-09-26: Histogenics Corporation Announces Approval Of Merger by Stockholders At Special Meeting

Financial news for HSGX dated on 2019-09-26: 21 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for HSGX dated on 2019-09-26: Histogenics shares are trading higher. Not seeing any news to justify the price action.

Financial news for HSGX dated on 2019-09-20: 15 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for HSGX dated on 2019-09-12: Histogenics shares are trading lower after the company adjourned its special meeting to vote on the proposed merger with Ocugen without conducting any business. The meeting was adjourned in order to solicit additional proxies for the proposal.

Financial news for HSGX dated on 2019-09-12: 28 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for HSGX dated on 2019-09-10: 22 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for HSGX dated on 2019-08-30: 18 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for HSGX dated on 2019-08-29: 23 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for HSGX dated on 2019-08-27: 12 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for HSGX dated on 2019-08-22: 12 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for HSGX dated on 2019-08-13: 16 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for HSGX dated on 2019-08-12: 17 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for HSGX dated on 2019-08-02: 29 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for HSGX dated on 2019-08-01: 28 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for HSGX dated on 2019-07-31: 28 Healthcare Stocks Moving In Tuesday's After-Market Session

Financial news for HSGX dated on 2019-06-27: Histogenics Files Form RW To Withdrawn Registration Statement For Recent Offering

Financial news for HSGX dated on 2019-04-08: Ocular Biotechs Histogenics, Ocugen Announce Stock-For-Stock Merger

Financial news for HSGX dated on 2019-04-08: Benzinga Pro's Top 8 Most-Searchd Tickers For Morning Of Mon., Apr. 8, 2019

Financial news for HSGX dated on 2019-04-08: Histogenics shares trading higher following news of merger with Ocugen.

Financial news for HSGX dated on 2019-04-08: Histogenics Shares Resume Trade, Up 82%

Financial news for HSGX dated on 2019-04-08: Histogenix Shares To Resume Trade At 7:30 a.m. EDT

Financial news for HSGX dated on 2019-04-08: UPDATE: Histogenix Deal In Stock-For-Stock Deal Whereby All Ocugen's Shares, Convertibles Will Be Converted To Histogenix

Common Stock, Warrants; Ocugen Will Hold ~90% OF Outstanding Shares

Financial news for HSGX dated on 2019-04-08: Histogenics, Ocugen Report Merger To Create Combined Publicly-Traded Co. Named Ocugen

Financial news for HSGX dated on 2019-04-08: Histogenics Shares Halted News Pending

Financial news for HSGX dated on 2019-03-19: Histogenics shares are trading higher on heavy volume despite no company-specific news from the session. The company on Friday announced a restructuring which includes cost cutting and cash conservation measures.

Financial news for HSGX dated on 2019-02-08: Histogenics Reports That Pursuant To Voluntary Adjustment Right, Co. Determined To Reduce Exercise Price Of 2018 Warrants From \$0.70 To \$0.01/Share

Financial news for HSGX dated on 2019-01-24: Histogenics 8-K Shows Board Approved Restructuring Plan Related To Reductions In Headcount, Will Impact 65% Of Co.'s Workforce; Sees 1-Time Charge For Severance \$1.4M In Q1

Financial news for HSGX dated on 2019-01-04: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Jan. 4, 2019

Financial news for HSGX dated on 2018-12-28: The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO

Financial news for HSGX dated on 2018-12-26: 5 Stocks To Watch For December 26, 2018

Financial news for HSGX dated on 2018-12-26: 55 Biggest Movers From Monday

Financial news for HSGX dated on 2018-12-24: Mid-Day Market Update: Dow Down Over 400 Points; Crude Oil Falls 2.7%

Financial news for HSGX dated on 2018-12-24: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for HSGX dated on 2018-12-24: Mid-Morning Market Update: Markets Open Lower; Vista Equity Partners to Acquire Mindbody For \$36.50/Share

Financial news for HSGX dated on 2018-12-24: Benzinga's Top Upgrades, Downgrades For December 24, 2018

Financial news for HSGX dated on 2018-12-24: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for HSGX dated on 2018-12-24: Histogenics shares are trading lower after the FDA said an additional clinical trial will be needed before it would accept submission of a Biologics License Application for NeoCart.

Financial news for HSGX dated on 2018-12-24: H.C. Wainwright Downgrades Histogenics to Neutral

Financial news for HSGX dated on 2018-12-21: FDA Tells Histogenics An Additional Clinical Trial Will Be Needed Before It Would Accept A Submission Of A Biologics License Application For NeoCart

Financial news for HSGX dated on 2018-11-30: The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings

Financial news for HSGX dated on 2018-11-29: Histogenics Reports Co., FDA Continue To Discuss NeoCart Phase 3 Trial Data, Potential Regulatory Pathway

Financial news for HSGX dated on 2018-11-29: Histogenics And FDA Continue To Discuss NeoCart Phase 3 Clinical Trial Data And Potential Regulatory Pathway; FDA Has Not Yet Decided Regarding BLA Submission

Financial news for HSGX dated on 2018-11-25: The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

Financial news for HSGX dated on 2018-11-15: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018

Financial news for HSGX dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for HSGX dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for HSGX dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for HSGX dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for HSGX dated on 2018-11-08: Histogenics Corporation - Common Stock Q3 EPS \$(0.24) Misses \$(0.20) Estimate

Financial news for HSGX dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for HSGX dated on 2018-11-02: The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug

Financial news for HSGX dated on 2018-11-01: Histogenics Reports It Will Continue To Discuss NeoCart Phase 3 Data With FDA And Potential Regulatory Pathway

Financial news for HSGX dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for HSGX dated on 2018-10-30: REMINDER: Histogenix Discussing Possibility of Filing BLA for NeoCart Despite it Not Meeting Its Primary Endpoint When Phase 3 Data Was Released 9/5/18

Financial news for HSGX dated on 2018-10-29: Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?

Financial news for HSGX dated on 2018-10-29: Histogenics Shares Move Sharply Lower On High Volume; REMINDER: Co. Expected To Meet With FDA Tomorrow To Discuss Possibly Filing BLA For NeoCart Despite It Not Meeting Its Primary Endpoint In Phase 3 Study

Financial news for HSGX dated on 2018-10-12: Stocks Which Set New 52-Week Low Yesterday, October 11th

Financial news for HSGX dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for HSGX dated on 2018-10-11: Stocks Which Set New 52-Week Low Yesterday, October 10th

Financial news for HSGX dated on 2018-10-08: 46 Biggest Movers From Friday

Financial news for HSGX dated on 2018-10-05: Mid-Afternoon Market Update: SMART Global Jumps Following Strong Q4 Results; Aytu BioScience Shares Slide

Financial news for HSGX dated on 2018-10-05: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for HSGX dated on 2018-10-05: Mid-Day Market Update: Dow Falls Over 200 Points; KemPharm Shares Plunge

Financial news for HSGX dated on 2018-10-05: Mid-Morning Market Update: Markets Mostly Lower; U.S. Unemployment Rate Drops To 3.7% In September

Financial news for HSGX dated on 2018-10-05: Histogenics Corporation Prices 26.155M Share Common Stock And Warrant Offering At \$0.65/Share

Financial news for HSGX dated on 2018-10-05: 23 Stocks Moving In Friday's Pre-Market Session

Financial news for HSGX dated on 2018-10-05: A Peek Into The Markets: US Stock Futures Flat, All Eyes On Jobs Report

Financial news for HSGX dated on 2018-10-05: 6 Stocks To Watch For October 5, 2018

Financial news for HSGX dated on 2018-10-04: Histogenics shares are trading down 36% after the company announced an offering of common stock and warrants.

Financial news for HSGX dated on 2018-10-04: Histogenics Announces Offering Of Common Stock And Warrants; No Size Disclosed

Financial news for HSGX dated on 2018-09-27: The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron

Financial news for HSGX dated on 2018-09-26: Histogenics shares are up 14.8% after the company announced it will meet with the FDA on October 30 to review late-stage NeoCart data and discuss a potential regulatory pathway.

Financial news for HSGX dated on 2018-09-26: Histogenics To Meet With FDA To Discuss NeoCart Phase 3 Clinical Trial Data And Potential Regulatory Pathway

Financial news for HSGX dated on 2018-09-17: Stocks Which Set New 52-Week Low Friday, September 14

Financial news for HSGX dated on 2018-09-14: Stocks Which Set New 52-Week Low Yesterday, September 13th

Financial news for HSGX dated on 2018-09-14: The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut

Financial news for HSGX dated on 2018-09-12: Stocks Which Set New 52-Week Low Yesterday, September 11th

Financial news for HSGX dated on 2018-09-11: The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces \$175M Offering, Leadership Transition At Insulet

Financial news for HSGX dated on 2018-09-10: Stocks Which Set New 52-Week Low Friday, September 7th

Financial news for HSGX dated on 2018-09-07: Stocks Which Set New 52-Week Low Yesterday, September 6th

Financial news for HSGX dated on 2018-09-06: Stocks Which Set New 52-Week Low Yesterday, September 5th

Financial news for HSGX dated on 2018-09-06: The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

Financial news for HSGX dated on 2018-09-06: 54 Biggest Movers From Yesterday

Financial news for HSGX dated on 2018-09-05: Mid-Afternoon Market Update: Crude Oil Down 1.5%; Histogenics Shares Plunge

Financial news for HSGX dated on 2018-09-05: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for HSGX dated on 2018-09-05: Histogenics Slips Below \$1 Threshold After Knee Cartilage Candidate Fails Late-Stage Study

Financial news for HSGX dated on 2018-09-05: Mid-Day Market Update: NASDAQ Down Over 100 Points; ProQR Therapeutics Shares Surge

Financial news for HSGX dated on 2018-09-05: Mid-Morning Market Update: Markets Open Lower; HD Supply Earnings Top Expectations

Financial news for HSGX dated on 2018-09-05: Histogenics shares are trading down 71% after the company announced its Phase 3 trial of Neocart did not meet its primary endpoint in patients with knee cartilage damage.

Financial news for HSGX dated on 2018-09-05: Benzinga Pro's 6 Stocks To Watch Today

Financial news for HSGX dated on 2018-09-05: Histogenics Announces Phase 3 Clinical Trial of Neocart Did Not Meet the Primary Endpoint of a Statistically Significant Improvement in Pain and Function in a Dual Threshold Responder Analysis One Year After Treatment vs Microfracture

Financial news for HSGX dated on 2018-09-05: Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart in Patients With Knee Cartilage Damage

Financial news for HSGX dated on 2018-09-04: 44 Biggest Movers From Friday

Financial news for HSGX dated on 2018-08-09: Histogenics Corporation - Common Stock Q2 EPS \$(0.13) Beats \$(0.23) Estimate

Financial news for HSGX dated on 2018-05-16: 45 Biggest Movers From Yesterday

Financial news for HSGX dated on 2018-05-15: Melinta Therapeutics Shares Down 12.2% On ~3.5x Avg. Volume, No Apparent News

Financial news for HSGX dated on 2018-05-15: Histogenics Shares Down 12.2% On No News, Elevated Trading Volume

Financial news for HSGX dated on 2018-05-10: Histogenics Corporation - Common Stock Q1 EPS \$(0.52) Misses \$(0.22) Estimate

Financial news for HSGX dated on 2018-03-15: Histogenics Reports Q4 EPS \$(0.26) vs \$(0.27) Est.

Financial news for HSGX dated on 2018-01-26: Histogenics 13G Filing From Perceptive

Advisors Shows 8.8% Stake

Financial news for HSGX dated on 2018-01-24: Histogenics Filing Shows ~2.3M Share Common Stock Offering

Financial news for HSGX dated on 2018-01-09: Histogenics Corporation Announces Receipt of \$10M Up-front Payment for Japanese Neocart Agreement

Financial news for HSGX dated on 2017-12-22: 38 Biggest Movers From Yesterday

Financial news for HSGX dated on 2017-12-21: Cowen Out Positive On Histogenics, Says Licensing Agreement With MEDINET Will Fund, De-Risk, And Accelerate Path Towards NeoCart Commercialization In A Key Market

Financial news for HSGX dated on 2017-12-21: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for HSGX dated on 2017-12-21: 35 Stocks Moving In Thursday's Pre-Market Session

Financial news for HSGX dated on 2017-12-21: Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market; Includes \$10M Up-Front Payment With Potential Of \$87M In Total Milestones

Financial news for HSGX dated on 2017-11-09: Histogenics Reports Q3 EPS \$(0.23) vs \$(0.28) Est.

Financial news for HSGX dated on 2017-08-10: Histogenics Reports Q2 EPS \$(0.25) vs \$(0.30) Est.

Financial news for HSGX dated on 2017-07-11: Histogenics Offers Data From Collagen, Chondrocyte 3-D Bioprinting Study: 'Findings Augment Growing Body of Information to Support the Manufacture of Current and Next-Generation NeoCart(r) Implants'

Financial news for HSGX dated on 2017-06-27: UPDATE: Histogenics Says Co. On Track For Top-Line Data, Potential BLA Filing For Neocart In Q3 2018

Financial news for HSGX dated on 2017-06-27: Histogenics Completes Phase 3 Clinical Trial Of Neocart Enrollment

Financial news for HSGX dated on 2017-05-11: Histogenics Reports Q1 EPS \$(0.27) vs \$(0.35) Est.

Financial news for HSGX dated on 2017-05-08: Histogenics Gives Update on Agreement With the Japan Pharmaceuticals and Medical Devices Agency

Financial news for HSGX dated on 2017-03-16: S-3 from Histogenics Shows Registration for \$50M Mixed Securities Shelf Offering

Financial news for HSGX dated on 2017-03-16: Histogenics Reports Q4 EPS \$(0.63) vs \$(0.45) Est.

Financial news for HSGX dated on 2017-01-12: 12 Biggest Mid-Day Gainers For Thursday

Financial news for HSGX dated on 2017-01-12: Mid-Morning Market Update: Markets Open Lower; Delta Air Posts In-Line Profit

Financial news for HSGX dated on 2017-01-12: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for HSGX dated on 2017-01-12: A Peek Into The Markets: U.S. Stock Futures Drop Ahead Of Jobless Claims, Fed Speakers

Financial news for HSGX dated on 2017-01-12: Histogenics +54.61% Premarket @\$2.35; Co Announced Positive MRI Data from NeoCart Phase 1, Phase 2 Clinical Trials on Wednesday

Financial news for HSGX dated on 2017-01-11: Histogenics Announces Publication of MRI Data From NeoCart Phase 1 and Phase 2 Clinical Trials, Co. Says Data Shows Significant Improvement in Cartilage Quality Over First 24 Months After Treatment

Financial news for HSGX dated on 2016-12-19: H.C. Wainwright Initiates Coverage On Histogenics at Buy, Announces \$3.50 Target

Financial news for HSGX dated on 2016-11-10: Histogenics Reports Q3 EPS \$(0.70) vs \$(0.49 Est.

Financial news for HSGX dated on 2016-10-24: Histogenics Reports Phase 3 NeoCart

Trial Has Enrolled 183 Of The 245 Patients Needed TO Complete Trial

Financial news for HSGX dated on 2016-09-16: 10 Biggest Mid-Day Losers For Friday

Financial news for HSGX dated on 2016-09-16: Histogenics to Sell 2,653,553 Shares of Common Stock at \$2.25/Share

Financial news for HSGX dated on 2016-09-07: William Blair Downgrades Histogenics to Market Perform

Financial news for HSGX dated on 2016-08-12: BTIG Upgrades Histogenics To Buy, Sets \$3.50 Price Target

Financial news for HSGX dated on 2016-08-12: BTIG Research Upgrades Histogenics to Buy, Announces \$3.50 PT

Financial news for HSGX dated on 2016-08-11: Histogenics Reports Q2 EPS \$(0.61) vs \$(0.60) Est.

Financial news for HSGX dated on 2016-05-12: Histogenics Reports Q1 EPS \$(0.60) vs \$(0.59) Est.

Financial news for HSGX dated on 2016-03-10: Histogenics Q4 EPS (\$0.63) vs (\$0.59) est

Financial news for HSGX dated on 2016-02-02: Histogenics Corporation Provides NeoCart(r) Phase 3 Clinical Trial Enrollment Update, As Of Feb 2 Has Enrolled 123 Of 245 Patients

Financial news for HSGX dated on 2015-12-21: Histogenics Corporation Reports Amendment to NeoCart Phase 3 Clinical Trial Enrollment Criteria

Financial news for HSGX dated on 2015-11-12: Histogenics Reports Q3 EPS \$(0.61) vs \$(0.52) Est.

Financial news for HSGX dated on 2015-08-12: Histogenic Corp Reports Q2 Loss \$0.58 Vs Est Loss \$0.50

Financial news for HSGX dated on 2015-07-30: Histogenics Names Stephen Kennedy Chief Technology Officer.

Financial news for HSGX dated on 2015-07-15: Histogenics Corp. Names Dr. Gloria Matthews Chief Medical Officer

Financial news for HSGX dated on 2015-06-22: Histogenics Names Jonathan Lieber CFO

Financial news for HSGX dated on 2015-05-14: Histogenics Q1 EPS -\$0.60 vs -\$0.84 est

Financial news for HSGX dated on 2015-02-26: Histogenics Q4 EPS \$1.70 vs -\$0.66, May Not Compare

Financial news for HSGX dated on 2015-01-23: UPDATE: BTIG Research Initiates Coverage On Histogenics On NeoCart Potential

Financial news for HSGX dated on 2015-01-23: BTIG Research Initiates Histogenics With Buy

Financial news for HSGX dated on 2015-01-23: Benzinga's Top Initiations

Financial news for HSGX dated on 2015-01-23: BTIG Research Initiates Coverage on Histogenics at Buy, Announces \$13.00 PT

Financial news for HSGX dated on 2015-01-05: Benzinga's Top Initiations

Financial news for HSGX dated on 2015-01-05: Canaccord Genuity Initiates Histogenics With Buy

Financial news for HSGX dated on 2015-01-05: Canaccord Genuity Initiates Coverage on Histogenics at Buy, Announces \$16.50 PT

Financial news for HSGX dated on 2015-01-05: Cowen & Company Initiates Coverage on Histogenics at Outperform, Announces \$17.00 PT

Financial news for HSGX dated on 2015-01-05: Needham Initiates Coverage on Histogenics at Buy, Announces \$17.00 PT

Financial news for HSGX dated on 2015-01-05: Canaccord Genuity Initiates Coverage on Histogenics at Buy, Announces \$16.50 PT

Financial news for HSGX dated on 2014-12-03: Histogenics Shares Open for Trade at \$11.35/Share, Priced at \$11

Financial news for HSGX dated on 2014-12-03: Expected IPOs For December 3

Financial news for HSGX dated on 2014-12-02: Histogenics 5.9M Share IPO Priced at \$11/Share

Financial news for HSGX dated on 2014-11-14: Amended S-1 Filing from Histogenics Shows IPO of 4.285M Shares Expected in \$13-\$15/Share Range